Entry - #613559 - COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 7; COXPD7 - OMIM
# 613559

COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 7; COXPD7


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
12q24.31 Combined oxidative phosphorylation deficiency 7 613559 AR 3 MTRFR 613541
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal recessive
GROWTH
Other
- Failure to thrive
HEAD & NECK
Face
- Facial diplegia
Eyes
- Nystagmus
- Ophthalmoplegia
- Optic atrophy
- Visual impairment
- Ptosis
ABDOMEN
Gastrointestinal
- Paralytic ileus
- Difficulty chewing and swallowing
MUSCLE, SOFT TISSUES
- Hypotonia
- Muscle weakness
- Muscle atrophy
NEUROLOGIC
Central Nervous System
- Psychomotor regression
- Psychomotor retardation
- Dysarthria
- Ataxia
- Loss of independent ambulation
- Bulbar paresis
- Brain imaging shows lesions in the thalami, brainstem, and cerebellum
- Increased CSF lactate
Peripheral Nervous System
- Axonal polyneuropathy
- Areflexia
- Distal sensory impairment
LABORATORY ABNORMALITIES
- Increased serum lactate
- Fibroblasts show decreased activity of mitochondrial respiratory complex I, complex III, complex IV, and complex V
MISCELLANEOUS
- Onset in early childhood
- Progressive disorder
- Two families have been reported (September 2010)
MOLECULAR BASIS
- Caused by mutation in the mitochondrial translation release factor in rescue gene (MTRFR, 613541.0001)
Combined oxidative phosphorylation deficiency - PS609060 - 59 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p34.2 Combined oxidative phosphorylation deficiency 35 AR 3 617873 TRIT1 617840
1q21.2 Combined oxidative phosphorylation deficiency 21 AR 3 615918 TARS2 612805
1q25.1 ?Combined oxidative phosphorylation deficiency 38 AR 3 618378 MRPS14 611978
2p16.1 Combined oxidative phosphorylation deficiency 13 AR 3 614932 PNPT1 610316
2p11.2 Combined oxidative phosphorylation deficiency 51 AR 3 619057 PTCD3 614918
2q33.1 ?Combined oxidative phosphorylation deficiency 25 AR 3 616430 MARS2 609728
2q33.1 Combined oxidative phosphorylation deficiency 53 AR 3 619423 C2orf69 619219
2q33.3 Combined oxidative phosphorylation deficiency 44 AR 3 618855 FASTKD2 612322
2q36.1 Combined oxidative phosphorylation deficiency 16 AR 3 615395 MRPL44 611849
3p25.2 Combined oxidative phosphorylation deficiency 56 3 620139 TAMM41 614948
3p25.1 ?Combined oxidative phosphorylation deficiency 50 AR 3 619025 MRPS25 611987
3p14.1 Combined oxidative phosphorylation deficiency 28 AR 3 616794 SLC25A26 611037
3q11.2 Combined oxidative phosphorylation deficiency 48 AR 3 619012 NSUN3 617491
3q12.3 Combined oxidative phosphorylation deficiency 30 AR 3 616974 TRMT10C 615423
3q22.1 Combined oxidative phosphorylation deficiency 9 AR 3 614582 MRPL3 607118
3q23 Combined oxidative phosphorylation deficiency 5 AR 3 611719 MRPS22 605810
3q25.32 Combined oxidative phosphorylation deficiency 1 AR 3 609060 GFM1 606639
4q31.3 ?Combined oxidative phosphorylation deficiency 41 AR 3 618838 GATB 603645
5q13.3 Combined oxidative phosphorylation deficiency 39 AR 3 618397 GFM2 606544
6p25.1 ?Combined oxidative phosphorylation deficiency 19 AR 3 615595 LYRM4 613311
6p25.1 Combined oxidative phosphorylation deficiency 14 AR 3 614946 FARS2 611592
6p21.33 Combined oxidative phosphorylation deficiency 20 AR 3 615917 VARS2 612802
6p21.1 Combined oxidative phosphorylation deficiency 8 AR 3 614096 AARS2 612035
6q13 Combined oxidative phosphorylation deficiency 10 AR 3 614702 MTO1 614667
6q21 Combined oxidative phosphorylation deficiency 40 AR 3 618835 QRSL1 617209
6q25.1 Combined oxidative phosphorylation deficiency 11 AR 3 614922 RMND1 614917
8q21.13 ?Combined oxidative phosphorylation deficiency 47 AR 3 618958 MRPS28 611990
9q34.3 Combined oxidative phosphorylation deficiency 36 AR 3 617950 MRPS2 611971
10q22.2 Combined oxidative phosphorylation deficiency 2 AR 3 610498 MRPS16 609204
10q26.11 Combined oxidative phosphorylation deficiency 18 AR 3 615578 SFXN4 615564
11q14.1 Combined oxidative phosphorylation deficiency 24 AR 3 616239 NARS2 612803
12q14.1 Combined oxidative phosphorylation deficiency 3 AR 3 610505 TSFM 604723
12q24.31 Combined oxidative phosphorylation deficiency 42 AR 3 618839 GATC 617210
12q24.31 Combined oxidative phosphorylation deficiency 7 AR 3 613559 MTRFR 613541
13q12.12 Combined oxidative phosphorylation deficiency 31 AR 3 617228 MIPEP 602241
13q34 Combined oxidative phosphorylation deficiency 27 AR 3 616672 CARS2 612800
14q13.2 Combined oxidative phosphorylation deficiency 54 AR 3 619737 PRORP 609947
14q23.1 Peripheral neuropathy with variable spasticity, exercise intolerance, and developmental delay AR 3 616539 TRMT5 611023
15q22.31 Combined oxidative phosphorylation deficiency 15 AR 3 614947 MTFMT 611766
16p13.3 Combined oxidative phosphorylation deficiency 32 AR 3 617664 MRPS34 611994
16p12.2 Combined oxidative phosphorylation deficiency 12 AR 3 614924 EARS2 612799
16p11.2 Combined oxidative phosphorylation deficiency 4 AR 3 610678 TUFM 602389
17p13.3 ?Combined oxidative phosphorylation deficiency 43 AR 3 618851 TIMM22 607251
17p13.2 Combined oxidative phosphorylation deficiency 33 AR 3 617713 C1QBP 601269
17p12 Combined oxidative phosphorylation deficiency 17 AR 3 615440 ELAC2 605367
17p11.2 ?Combined oxidative phosphorylation deficiency 49 AR 3 619024 MEIF2 615498
17q11.2 Combined oxidative phosphorylation deficiency 58 AR 3 620451 TEFM 616422
17q22 ?Combined oxidative phosphorylation deficiency 46 AR 3 618952 MRPS23 611985
17q25.1 ?Combined oxidative phosphorylation deficiency 34 AR 3 617872 MRPS7 611974
17q25.3 ?Combined oxidative phosphorylation deficiency 45 AR 3 618951 MRPL12 602375
18q21.1 ?Combined oxidative phosphorylation deficiency 22 AR 3 616045 ATP5F1A 164360
19p13.3 Combined oxidative phosphorylation deficiency 55 AD, AR 3 619743 POLRMT 601778
19p13.3 Combined oxidative phosphorylation deficiency 37 AR 3 618329 MICOS13 616658
19p13.11 Combined oxidative phosphorylation deficiency 23 AR 3 616198 GTPBP3 608536
20p12.3 Combined oxidative phosphorylation deficiency 57 AR 3 620167 CRLS1 608188
20q11.22 Combined oxidative phosphorylation deficiency 52 AR 3 619386 NFS1 603485
21q21.3 Combined oxidative phosphorylation deficiency 59 AR 3 620646 MRPL39 611845
22q12.3 ?Combined oxidative phosphorylation deficiency 29 AR 3 616811 TXN2 609063
Xq26.1 Combined oxidative phosphorylation deficiency 6 XLR 3 300816 AIFM1 300169

TEXT

A number sign (#) is used with this entry because combined oxidative phosphorylation deficiency-7 (COXPD7) is caused by homozygous mutation in the C12ORF65 gene (MTRFR; 613541) on chromosome 12q24.

For a discussion of genetic heterogeneity of combined oxidative phosphorylation deficiency, see COXPD1 (609060).


Clinical Features

Antonicka et al. (2010) reported 3 patients, including 2 sibs, with a complex phenotype associated with a combined mitochondrial oxidative phosphorylation deficiency. The first child was a girl, born of consanguineous Turkish parents, who showed failure to thrive and psychomotor regression beginning at age 1 year. At 18 months, she had psychomotor retardation, ataxia, and ptosis. She later developed nystagmus, severe optic atrophy, decreased vision, and ophthalmoplegia. Brain MRI showed bilateral lesions in the thalami, brainstem, and medulla spinalis, consistent with a diagnosis of Leigh syndrome (256000). By the time of her death at age 8 years, she was hypermobile with ataxia and used a wheelchair. The second family was Dutch and had 2 affected boys. Both had initial normal development but developed nystagmus in early childhood, followed by developmental regression at ages 3-4 and 7 years, respectively. One patient became wheelchair-dependent at age 8, and ventilator-dependent with a gastrostomy tube due to paralytic ileus at age 14. Examination at age 20 years showed significant ocular involvement with optic atrophy and diminished vision, divergent squint, and incomplete external ophthalmoplegia. Other features included bulbar paresis with facial diplegia, difficulty chewing and swallowing, and mild dysarthria. He also had evidence of an axonal polyneuropathy with global muscle atrophy, hypotonia, areflexia, and decreased distal sensory functions. The affected brother had a similar disease course and died at age 22 years. Brain MRI showed extensive signal abnormalities in the brainstem and signal abnormalities in the cerebellar white matter and thalamus. Magnetic resonance spectroscopy of the brainstem revealed highly elevated lactate. Antonicka et al. (2010) noted that the disease progression in these patients was slower than that seen in patients with classic Leigh syndrome.


Biochemical Features

By laboratory studies of fibroblasts isolated from patients with a complex neurologic disorder, Antonicka et al. (2010) found severe assembly defects of mitochondrial respiratory complexes I, IV, and V, with a milder defect in the assembly of complex III. There was also a 30% decrease in the synthesis of mtDNA-encoded polypeptides with normal transcript levels, indicating a deficiency of mitochondrial translation. Mitochondrial ribosomal proteins were normal on Western blot analysis.


Inheritance

COXPD7 is inherited in an autosomal recessive manner (Antonicka et al., 2010).


Molecular Genetics

By genomewide linkage analysis followed by candidate gene sequencing in a patient with a combined oxidative phosphorylation defect born of consanguineous Turkish parents, Antonicka et al. (2010) identified a homozygous mutation in the C12ORF65 gene (613541.0001). Two affected brothers from a Dutch family with the same disorder carried a different homozygous mutation (613541.0002).


REFERENCES

  1. Antonicka, H., Ostergaard, E., Sasarman, F., Weraarpachai, W., Wibrand, F., Pedersen, A. M. B., Rodenburg, R. J., van der Knaap, M. S., Smeitink, J. A. M., Chrzanowska-Lightowlers, Z. M., Shoubridge, E. A. Mutations in C12orf65 in patients with encephalomyopathy and a mitochondrial translation defect. Am. J. Hum. Genet. 87: 115-122, 2010. [PubMed: 20598281, images, related citations] [Full Text]


Creation Date:
Cassandra L. Kniffin : 9/16/2010
carol : 02/24/2021
carol : 11/22/2013
carol : 7/21/2011
wwang : 9/20/2010
ckniffin : 9/16/2010

# 613559

COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 7; COXPD7


SNOMEDCT: 763204003;   ORPHA: 254930;   DO: 0111487;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
12q24.31 Combined oxidative phosphorylation deficiency 7 613559 Autosomal recessive 3 MTRFR 613541

TEXT

A number sign (#) is used with this entry because combined oxidative phosphorylation deficiency-7 (COXPD7) is caused by homozygous mutation in the C12ORF65 gene (MTRFR; 613541) on chromosome 12q24.

For a discussion of genetic heterogeneity of combined oxidative phosphorylation deficiency, see COXPD1 (609060).


Clinical Features

Antonicka et al. (2010) reported 3 patients, including 2 sibs, with a complex phenotype associated with a combined mitochondrial oxidative phosphorylation deficiency. The first child was a girl, born of consanguineous Turkish parents, who showed failure to thrive and psychomotor regression beginning at age 1 year. At 18 months, she had psychomotor retardation, ataxia, and ptosis. She later developed nystagmus, severe optic atrophy, decreased vision, and ophthalmoplegia. Brain MRI showed bilateral lesions in the thalami, brainstem, and medulla spinalis, consistent with a diagnosis of Leigh syndrome (256000). By the time of her death at age 8 years, she was hypermobile with ataxia and used a wheelchair. The second family was Dutch and had 2 affected boys. Both had initial normal development but developed nystagmus in early childhood, followed by developmental regression at ages 3-4 and 7 years, respectively. One patient became wheelchair-dependent at age 8, and ventilator-dependent with a gastrostomy tube due to paralytic ileus at age 14. Examination at age 20 years showed significant ocular involvement with optic atrophy and diminished vision, divergent squint, and incomplete external ophthalmoplegia. Other features included bulbar paresis with facial diplegia, difficulty chewing and swallowing, and mild dysarthria. He also had evidence of an axonal polyneuropathy with global muscle atrophy, hypotonia, areflexia, and decreased distal sensory functions. The affected brother had a similar disease course and died at age 22 years. Brain MRI showed extensive signal abnormalities in the brainstem and signal abnormalities in the cerebellar white matter and thalamus. Magnetic resonance spectroscopy of the brainstem revealed highly elevated lactate. Antonicka et al. (2010) noted that the disease progression in these patients was slower than that seen in patients with classic Leigh syndrome.


Biochemical Features

By laboratory studies of fibroblasts isolated from patients with a complex neurologic disorder, Antonicka et al. (2010) found severe assembly defects of mitochondrial respiratory complexes I, IV, and V, with a milder defect in the assembly of complex III. There was also a 30% decrease in the synthesis of mtDNA-encoded polypeptides with normal transcript levels, indicating a deficiency of mitochondrial translation. Mitochondrial ribosomal proteins were normal on Western blot analysis.


Inheritance

COXPD7 is inherited in an autosomal recessive manner (Antonicka et al., 2010).


Molecular Genetics

By genomewide linkage analysis followed by candidate gene sequencing in a patient with a combined oxidative phosphorylation defect born of consanguineous Turkish parents, Antonicka et al. (2010) identified a homozygous mutation in the C12ORF65 gene (613541.0001). Two affected brothers from a Dutch family with the same disorder carried a different homozygous mutation (613541.0002).


REFERENCES

  1. Antonicka, H., Ostergaard, E., Sasarman, F., Weraarpachai, W., Wibrand, F., Pedersen, A. M. B., Rodenburg, R. J., van der Knaap, M. S., Smeitink, J. A. M., Chrzanowska-Lightowlers, Z. M., Shoubridge, E. A. Mutations in C12orf65 in patients with encephalomyopathy and a mitochondrial translation defect. Am. J. Hum. Genet. 87: 115-122, 2010. [PubMed: 20598281] [Full Text: https://doi.org/10.1016/j.ajhg.2010.06.004]


Creation Date:
Cassandra L. Kniffin : 9/16/2010

Edit History:
carol : 02/24/2021
carol : 11/22/2013
carol : 7/21/2011
wwang : 9/20/2010
ckniffin : 9/16/2010